Clinical Trials
71 trialsDP-04
AstraZeneca
DESCENT-1
A2 Biotherapeutics Inc.
ELEPHAS-02
Elephas
Evaluation of Improved Onboard Patient Imaging
Varian, a Siemens Healthineers Company
JPMS-DTC
Bayer
TraveraRTGx
Travera Inc
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Tempus AI
PREDAPT-HNSCC2
Cofactor Genomics, Inc.
CAMPERR
Adela, Inc
SCORE
Natera, Inc.
ELEPHAS-05
Elephas
Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma
Pharmassist Ltd
PETRiS
XEOS Medical
NEUTROFLOW
OncoHost Ltd.
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
TScan Therapeutics, Inc.
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
SYMTECH01
Aptar Digital Health
Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma
Hookipa Biotech GmbH
ORACLE
Guardant Health, Inc.
PREMIER
RefleXion Medical
DELFI-L101
Delfi Diagnostics Inc.
ProNiHN
Bristol-Myers Squibb
Observational Study of Nivolumab in Participants in Germany With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Progressing on or After Platinum-Based Therapy
Bristol-Myers Squibb
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)
Celgene
A Multicenter Cancer Biospecimen Collection Study
Cofactor Genomics, Inc.
PREFER
Labcorp Corporation of America Holdings, Inc
Detection of Oral and Throat Cancers Using OralViome Cancer Testing System
Viome
Validity of Viome's Oral/throat Cancer Test
Viome
ROOT
Taproot Health
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment
Proteocyte Diagnostics Inc.
Evaluation of Oral Potentially Malignant Disorders (OPMDs) with STRATICYTEâ¢
Proteocyte Diagnostics Inc.
QUANTUM
VitaMed Research LLC
ETCETERA
Dyameo
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Sanguine Biosciences
Real-World Evidence and Treatment Patterns: Head and Neck Cancer
Bristol-Myers Squibb
A Study to Assess Safety of Nivolumab in Routine Oncology Practice in China
Bristol-Myers Squibb
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Fate Therapeutics
Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
RIFTOS MKI
Bayer
Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences
Power Life Sciences Inc.
Discovering Factors in Head and Neck Cancer Patients' Clinical Study Experiences
Power Life Sciences Inc.
Clinical Evaluation of Genetron TERT/BRAF PCR Kit in Thyroid Cancer Patients
Genetron Health
Clinical Study of Pan-cancer DNA Methylation Test in Plasma
Wuhan Ammunition Life-tech Co., Ltd
This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.
Repertoire Immune Medicines
DETECT
Boryung Pharmaceutical Co., Ltd
VOLUME-PRO
Bristol-Myers Squibb
Effectiveness and Safety of Nivolumab in Participants That Have Head and Neck Cancer That Has Come Back or Has Spread
Bristol-Myers Squibb
A Study of Treatment Patterns and Clinical Outcomes in First Line Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (1L R/M SCCHN) Participants in Europe
Bristol-Myers Squibb